Summary of Global Pharmaceutical Licensing Agreements and Financing Events from September 16 to September 22.

This week, multinational pharmaceutical companies including Sanofi, Bayer, Gilead Sciences, Novo Nordisk, and Pfizer have been notably active.

This article will use Pfizer as an example to teach you how to quickly learn to read Pharma/Biotech financial reports.

Pathios Therapeutics Secures $25M in Series B Funding for Cancer Drug Development.

Medincell and AbbVie Partner to Co-Develop Six Long-Acting Injectables.

On April 10, 2024, Vertex Pharmaceuticals ("Vertex") and Alpine Immune Sciences ("Alpine") announced that the parties entered into a definitive agreement. the parties have entered into a definitive agreement.

On April 12, 2024, Arvinas announced that it has entered into an exclusive strategic license agreement with Novartis to collaborate on the development of Arvinas' second-generation androgen receptor (AR) degrader, ARV-766.

On February 28th, US-based Viatris and Swiss firm Idorsia launched a major R&D partnership, with Viatris securing exclusive global rights for two Phase 3 drugs, Selatogrel and Cenerimod, and options for future joint projects.

clinical-stage biopharma atai Life Sciences (NASDAQ: ATAI), focused on transforming mental health treatment, announced a strategic investment in Beckley Psytech, cementing its position as the bio-pharma leader with the broadest portfolio of clinical-stage psychedelic drug candidates.

On February 21, 2024, Innovent Biologics and ImmVirX unveiled a partnership for clinical research on a combo therapy using sintilimab and the cancer-fighting virus IVX037.

Hutchmed and Inmagene have exercised licensing options for two drug candidates, IMG-007 and IMG-004, as per their strategic collaboration agreement.

On January 24, 2024, Novo Nordisk partnered with EraCal Therapeutics to co-develop an appetite and weight control drug.